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ABSTRACT 57 
 58 
Background: It is not known whether the protective effects of physical activity (PA) on 59 
cardiovascular disease (CVD) reported in high income countries (mainly recreational PA) is also 60 
observed in lower income countries (mainly non-recreational PA). We examined whether 61 
different levels and types of PA are associated with lower mortality and cardiovascular disease 62 
(CVD) in countries at different economic levels. 63 
Methods: In this prospective cohort study total PA was assessed using the International Physical 64 
Activity Questionnaire in 130 843 participants from 17 countries. Mortality and CVD were 65 
recorded during 6·9 years of follow-up. The effects of PA were adjusted for socio-demographic 66 
factors and other risk factors taking into account household, community and country clustering. 67 
Findings: Compared to low PA levels (<600 METS per week or <150 minutes/week of 68 
moderate intensity PA), moderate (600 to 3000 or 150 to 750 minutes/week) and high PA levels 69 
(>3000 or >750 minutes/week) were associated with a graded reductions in mortality (hazard 70 
ratios =0·80 [0·74, 0·87] and 0·65 [0·60, 0·71], p<0·0001 for trend), and major CVD 71 
(myocardial infarction, stroke and heart failure; (0·86 [0·78, 0·93], p<0·001 for trend). 72 
Increasing PA was associated with lower risk of CVD and mortality in high, middle and low 73 
income countries. The adjusted population attributable fraction for not meeting the PA guidelines 74 
was 8·0% and 4·6%, and not meeting high PA levels was 13·0% and 9·5% for mortality and 75 
major CVD, respectively. Both recreational and non-recreational PA were associated with 76 
benefits. 77 
Interpretation: Increasing recreational and non-recreational PA are associated with a lower risk 78 
of mortality and CVD events in low, middle and high income countries. Enhancing PA is a 79 
4 
simple, widely applicable, low cost global strategy which could avoid about 10% of deaths and 80 
CVD in middle age. 81 
Funding: Funding sources listed at end of paper. 82 
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Cardiovascular disease (CVD) is the leading cause of death worldwide1 and a major economic 86 
global burden.2 Despite reductions in CVD mortality in high income countries (HIC), global 87 
CVD mortality increased by 41% between 1990 and 2013; largely driven by rises in low and 88 
lower-middle-income countries.3 Indeed, 70% of global CVD deaths come from low and middle 89 
income countries where it is the largest cause of death.4,5 It has been estimated that 23% of the 90 
world’s population was insufficiently active6 and the WHO has recommended a decrease in 91 
insufficient PA of 10% by 2020.7 92 
 93 
Numerous studies from HIC have reported significant inverse associations of PA with mortality 94 
and CVD morbidity.8 but such data from low and middle income countries are sparse and limited 95 
to a few small studies.9-11 In addition, studies of PA have focused primarily on recreational PA 96 
(which is more common in HIC but less common in poorer countries),8,11 with less evidence on 97 
the benefits of other forms of  PA such as during transportation,12 house work and occupational 98 
PA.13  99 
 100 
In the Prospective Urban Rural Epidemiologic (PURE) study being conducted in 17 high, middle 101 
and low income countries, we examined whether PA is associated with lower risk of mortality 102 
and CVD in countries at varying economic levels and whether these associations differ by type 103 
of PA. 104 
 105 
METHODS 106 
The PURE study includes participants from three HICs (Canada, Sweden, United Arab 107 
Emirates); seven upper middle income countries ([UMIC] Argentina, Brazil, Chile, Poland, 108 
6 
Turkey, Malaysia, South Africa); three lower middle income countries ([LMIC] China, 109 
Colombia, Iran); and four low income countries ([LIC] Bangladesh, India, Pakistan, 110 
Zimbabwe).14 Country economic level was based on World Bank classifications in 2006. The 111 
choice and number of countries selected in PURE reflects a balance between involving a large 112 
number of communities in countries at different economic levels with substantial heterogeneity 113 
in social and economic circumstances versus the feasibility of centres to successfully achieve 114 
long-term follow-up.  115 
 116 
Within each country, urban and rural areas in and around selected cities and towns were 117 
identified to reflect the geographical diversity of the countries. Communities were defined based 118 
on the geographical clustering of common characteristics (sharing culture [as people of a similar 119 
culture reside in close geographic proximity], socioeconomic status, and use of amenities, goods, 120 
and services) such as through a set of contiguous postal code areas or group of streets or a small 121 
village. The number of communities selected in each country varied. In some countries (eg, 122 
India, China, Canada, and Colombia), communities from several states/provinces were included 123 
to capture diversity, socioeconomic status, culture, and environments. In other countries (eg, 124 
Iran, Poland, Sweden, and Zimbabwe), fewer communities were selected. This strategy 125 
facilitated recruitment of individuals from different economic, cultural and geographical settings 126 
(rural and urban) around the globe. 127 
 128 
Within each defined community, households were approached and individuals between 35 and 129 
70 years of age who intended to live at their current address for at least another four years were 130 
invited to participate in the study. The method of approaching households differed between 131 
7 
countries based on feasibility but was consistent across sites within each country. For example, 132 
in rural areas of India and China, a community announcement was made to the village through 133 
contact of a community leader, followed by in-person door-to-door visits of all households. In 134 
contrast in Canada, initial contact was by mail followed by telephone invitations to attend a 135 
central clinic. For each household at least three attempts at contact were made. All eligible 136 
residents of the household were invited and those who provided informed consent were recruited. 137 
Household participation rate was 86%. Recruitment started in a vanguard phase in Karnataka, 138 
India in January 2003; however most communities recruited between January 2005 and 139 
December 2010. See Supplementary Appendix provides more detail on sampling. The study was 140 
approved by local institutional research ethics boards. 141 
 142 
Socio-demographic factors, medical history, lifestyle behaviours and risk factors were recorded  143 
using standardized measures and procedures.11 One-week total PA was assessed using the long-144 
form International Physical Activity Questionnaire (IPAQ)15 and calculated as a total of 145 
occupation, transportation, housework and recreational activity reported in metabolic equivalents 146 
(MET) * minutes/ week. Physical activity is also reported in minutes/week of moderate intensity 147 
PA using the equation where minutes reported in each PA domain on the IPAQ by the participant 148 
are weighted relative to moderate intensity PA: 149 
Minutes/week  = 0.825*walking minutes + 1*moderate minutes + 1.375*garden minutes + 150 
1.5*cycling minutes + 2*vigorous minutes 151 
Total PA was categorized as low (<600 MET*minute/week), moderate (600-3000 152 
MET*minute/week) and high (≥3000 MET*minute/week) PA levels, which corresponds to <150 153 
minutes/week, 150-750 minutes/week and ≥750 minutes per week of moderate intensity PA. 154 
8 
Physical activity was also dichotomized as meeting or not meeting current PA guidelines 155 
(meeting guideline is PA ≥600MET*minute/week as per the IPAQ15 or PA ≥150 minutes/week 156 
of moderate intensity PA as per the WHO16) with periods of less than 10 minutes of PA not 157 
included as per the IPAQ guidelines.15 16We also further categorized the high PA category into a 158 
lower-high PA level and an upper-high PA level by the median value of the high PA category of 159 
6453 MET*minutes/week to investigate whether the effect of very high PA levels was graded.  160 
PA was categorized into recreational PA and non-recreational PA (occupational, transportation 161 
and housework).  162 
 163 
The clinical outcomes of interest during follow-up were: mortality plus major CVD (CVD 164 
mortality plus incident MI, stroke, and heart failure), either as a composite or separately 165 
(Supplementary Appendix). In most low and middle income countries there was no central 166 
system of death or event registration. We therefore obtained information on prior medical illness 167 
and medically certified cause of death where available, and recorded best available information 168 
from close family or friends in order to arrive at a probable diagnosis or cause of death. Death 169 
certificates (available in 100% of deaths), medical records (MI: 49.4%, stroke 80.8% and heart 170 
failure: 76.2%), household interviews and other sources of information was used. We also used 171 
Verbal Autopsies to ascertain cause of death in addition to medical records which were reviewed 172 
by a health professional.17 To ensure a standard approach and accuracy for classification of 173 
events across all countries and over time, a selection of cases from each country annually was 174 
adjudicated both locally and also by the adjudication chair, and if necessary further training was 175 
provided.  176 
 177 
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Statistical analyses 178 
The primary analyses were conducted excluding participants who reported having CVD at 179 
baseline. Baseline characteristics were described for the entire cohort and stratified by low, 180 
moderate, and high level of total PA. Total and domain specific PA values were not normally 181 
distributed and are presented as median and inter-quartile range (IQR).18 Kruskal-Wallis test and 182 
Jonckheere -Terpstra test19,20 were used to test the heterogeneity and trend across the four 183 
country income levels (HIC, UMIC, LMIC, or LIC), respectively. For the two categorical PA 184 
variables: level of total PA and whether meeting PA guideline, we calculated frequencies and 185 
compared their difference and trend across the country income levels using Chi-square test and 186 
Cochrane-Armitage test,21,22 as appropriate. 187 
 188 
Age-sex-standardized incidence rates for all outcomes were calculated for levels of total PA and 189 
whether meeting PA guidelines.23 To examine the association between PA variables and 190 
outcomes, we used the marginal Cox proportional hazard model .24,25 Models were adjusted for 191 
age, sex, education, country income level, residency (urban vs. rural), family history of CVD and 192 
smoking status (current and ever smoker vs. never smoker- cigarette, cigar and pipe smoking) 193 
taking into account three levels of clustering. We conducted further analyses using wealth index 194 
and household income (in separate models) in place of education but these did not change the 195 
results. In addition, we further adjusted for body mass index (BMI).  196 
 197 
Adjusted population attributable fractions related to not meeting PA guidelines and not achieving 198 
high PA levels were calculated to quantify the benefit of PA, using the method developed by 199 
Chen et al.26 To minimize the potential for reverse causation, we conducted sensitivity analyses 200 
10 
by excluding participants who experienced CVD events in the first two years of follow-up. 201 
Additional analyses were also conducted including PURE participants who had CVD at baseline 202 
(n=141 945) and these yielded similar results. We estimated the effect of total PA on the 203 
outcomes by country income level, sex, age (<50 or ≥50 years), BMI (<25 kg/m2 or ≥25 kg/m2), 204 
waist-hip-ratio (above 0·85 for female, 0·90 for male), and smoking, hypertension, and diabetes. 205 
 206 
To assess and compare the effect of recreational PA vs. non-recreation PA, we fitted the adjusted 207 
marginal Cox model with restricted cubic spline with four knots at the 5th, 35th, 65th and 95th 208 
percentiles for overall and non-recreational PA.27 Because 55% participants had no recreational 209 
PA, we chose 50th, 65th, 80th and 95th percentile as the knots. We also examined whether the 210 
association between PA and outcomes varied by country income and by type of PA (total, 211 
recreational or non-recreational) using tests of interaction to compare the effects between HIC 212 
and UMIC vs LMIC and LIC. All analyses were conducted using SAS 9.4, for UNIX operating 213 
system (SAS Institute, Cary, US) and R software, version 3.2.5, for Windows system. 214 
 215 
RESULTS 216 
A total of 168 916 participants were enrolled, of whom 141 945 had completed the IPAQ and the 217 
analyses were limited to the 130 843 participants without pre-existing CVD. Table 1 presents 218 
participant characteristics stratified by low, moderate, and high PA levels. Participant 219 
characteristics were not materially different in most features across the three groups with the 220 
exception of a lower proportion of males in the moderate PA group compared to the others and a 221 
greater proportion of family history of CVD in the high PA group. The prevalence of 222 
11 
hypertension and diabetes were lower with higher PA. There was no association between diet 223 
score or body mass index with PA levels. 224 
 225 
Table 2 presents PA by country income levels in both MET*minutes/week and minutes/week of 226 
moderate intensity PA. There was a trend towards lower total PA and recreational PA from HIC 227 
to LIC (p<0.0001 for both), but not for non-recreational PA. A large majority of participants met 228 
the PA guidelines, but fewer than half of the participants reached high levels of PA. 229 
 230 
During the mean follow-up of 6·9 ± 3·0 years there were 5334 deaths,1294 CVD deaths and 231 
4040 non-CVD deaths, 1987 individuals with incident MI, 2086 with incident stroke, and 386 232 
with new  heart failure (Supplemental Table 1). When stratified by PA level, there was a graded 233 
reduction in age and sex adjusted event rates for all outcomes from low to moderate to high PA 234 
(p<0·0001 for trend for all events except for stroke (p=0·0010)) except heart failure  (Table 3).  235 
Those meeting the guidelines for minimal PA had lower age and sex adjusted rates of all 236 
outcomes (Table 3). 237 
 238 
Participating in PA at or above the PA guidelines was associated with significant lower rates of 239 
outcomes compared to those participants not meeting the PA guidelines  ≥600 240 
MET*minute/week as per the IPAQ15 or PA ≥150 minutes/week of moderate intensity PA as per 241 
the WHO16). In fully adjusted models, meeting PA guidelines was associated with hazard ratios 242 
(HR) [95% confidence interval] of 0·78 [0·74, 0·83] for mortality plus major CVD, 0·72 [0·67, 243 
0·77] for mortality and 0·80 [0·74, 0·86] for major CVD (p<0·0001 for all). 244 
 245 
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In fully adjusted models increasing levels of PA (moderate and high) were associated with lower 246 
HR for mortality plus major CVD, mortality and major CVD compared to those with low levels 247 
of total PA (p<0·0001 p<0·0001 and p=0·0005 for trend, respectively; Figure 1). When adjusted 248 
for either wealth index or household income in place of education, HR did not change 249 
(Supplemental Tables 2 and 3). In addition, high PA was associated with a lower HR compared 250 
to moderate PA for all outcomes. Dichotomizing high PA levels above or below the median 251 
value in this group off 6453 MET*minutes/week did not show further reductions in risk 252 
(Supplemental Table 4). Increasing PA was also associated with lower HR in CVD mortality, 253 
non-CVD mortality and MI (Supplemental Table 5). With further adjustment for BMI, the HR 254 
were slightly attenuated but remained significant (Supplemental Table 6). Excluding participants 255 
who had a CVD event within the first two years of follow-up (to account for potential reverse 256 
causality if sick individuals were less active), the results were consistent for all outcomes 257 
(Supplemental Table 7). 258 
 259 
Survival curves (Supplemental Figure 1) for low, moderate, and high PA levels for our three 260 
primary outcomes of mortality plus major CVD, mortality and major CVD indicated a lower risk 261 
as PA increased (p<0·0001).  262 
 263 
The five-year adjusted population attributable fraction of not meeting the PA guidelines was 264 
5·3%, 8·0% and 4·6% for  mortality plus major CVD, mortality and major CVD, respectively 265 
(Supplemental Figure 2). These values were higher (10·3%, 13·0% and 9·5%, respectively), for 266 
not achieving high PA.  267 
 268 
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Increasing PA was associated with lower risk  mortality in a range of subgroups (Figure 2). 269 
Compared to low levels of PA, moderate and high levels of PA were associated with a lower 270 
graded risk for mortality regardless of sex, age, and in the presence of risk factors. 271 
 272 
Increasing PA was associated with significantly lower risk up to approximately 3000 273 
MET*minutes/week (or 750 minutes/week of moderate intensity PA) with more modest benefits 274 
above that PA level (p<0·0001). (Figure 3). For recreational PA, increasing PA was associated 275 
with significantly lower risk up to approximately 600 MET*minutes/week (or 150 minutes/week 276 
of moderate intensity PA) (p=0·01) (as few had levels of PA higher than this), while for non-277 
recreational PA, increasing PA was associated with significantly lower risk up to approximately 278 
5000 MET*minutes/week (or 1250 minutes/week of moderate intensity PA) with more modest 279 
benefits above that PA level (p<0·0001). 280 
 281 
Increasing PA was associated with significantly lower risk for mortality plus major CVD in 282 
UMIC and LIC, mortality in UMIC, LMIC and LIC and major CVD in UMIC and LIC (Table 283 
4). When stratified by country income level (HIC + UMIC versus LMIC + LIC) there was a 284 
significant interaction between country income level and PA levels for total (p=0·0012) and 285 
recreational PA (p=0·0063) such that the HIC + UMIC had a lower risk with increasing PA level 286 
(Figure 4). This was less clear for non-recreational PA (p=0·063). 287 
 288 
DISCUSSION 289 
In this study involving 3 HIC, 7 UMIC, 3 LMIC, and 4 LIC countries, increasing PA was 290 
associated with a lower risk for mortality and incidence of major CVD. This lower risk was 291 
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present even at moderate levels of PA compared to low levels of PA, and was more marked at 292 
higher PA levels . The benefit of PA was present independent of the type of PA (recreational or 293 
non-recreational), a range of socio-economic and CVD risk factors, and was similar in various 294 
countries with differing income levels. 295 
 296 
In our study population of predominantly non-HIC residing participants, meeting the PA 297 
guidelines (150 minutes/week of moderate intensity of PA) was associated with a 22%, 28%, and 298 
20% lower risk for all-cause mortality plus major CVD, mortality and major CVD, respectively, 299 
resulting in adjusted population attributable fractions of 5·3%, 8·0% and 4·6%, respectively. 300 
These attributable fractions are similar to those reported by Lee et al.; 9·4% for mortality and 301 
5·8% for CVD in  HIC.9 In addition, we observed a graded effect such that participants at higher 302 
levels of PA had a lower risk than those participants engaging in moderate levels of PA. For 303 
example, compared to people at moderate levels of PA, participating in high levels of PA 304 
conferred an additional reduction in risk of 15%, 19% and 12% for mortality plus major CVD, 305 
mortality and major CVD, respectively. This benefit plateaued only at very high levels of PA 306 
(approximately 1250 minutes/week of moderate intensity of PA). Similar to previous studies of 307 
recreational PA in HIC,28,29 we did not observe any adverse efforts of PA on our outcomes even 308 
in the approximately 9000 participants who reported over 2500 minutes/week of moderate 309 
intensity of PA (equivalent to 17 times that of the PA guidelines). Therefore while participating 310 
at even low levels of PA confers benefit (30 minutes per day for five days a week), the benefit 311 
continues to increase up to high levels of total PA. Given these findings and that the affordability 312 
of other CVD interventions such as consuming fruits and vegetables,30 and taking  generic CVD 313 
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drugs is beyond the reach of many people in low and middle income countries,31 participating in 314 
PA represents a low cost approach to CVD prevention . 315 
 316 
When stratified by country income level there was a consistent reduction of risk with increasing 317 
PA. For HIC, meeting the PA guidelines was associated with a 30% lower risk for mortality, 318 
which is lower than the 11% reported in a meta-analysis of walking from a study conducted 319 
predominantly in HIC.12 However, this earlier study did not include participants in the high PA 320 
level of >3000 MET*minutes/week as ours did in which we found a continued benefit with 321 
increasing PA levels.  Studies in Iran and China also reported PA to be significantly associated 322 
with lower mortality in a dose-dependent manner.32,33 Notably, Matthew et al. reported a HR of 323 
0.61 [0.51-0.73] at the highest levels of PA of the Chinese women, which is similar to our HR of 324 
0.65 [0.60, 0.71]. These findings are consistent with what we found in the LMIC category of 325 
countries of which Iran and China accounted for the overwhelming majority of participants in 326 
our LMIC group.  327 
 328 
Increasing PA levels, was associated with a lower risk of mortality plus major CVD in higher 329 
and UMIC compared to lower middle and LIC for both total and recreational PA; there were less 330 
clear differences with respect to non-recreational PA. It is unclear why recreational PA may be 331 
less effective in the lower middle and LIC, however, very few participants from the countries 332 
participated in any recreational PA and so these findings may be swayed by a very small number 333 
of participants who are atypical of the general populations in poorer countries.  334 
 335 
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Few studies have assessed the association of non-recreational PA with outcomes. The available 336 
studies are relatively small and report inconsistent results.12,34-38 We found that increasing levels 337 
of both recreational PA and non-recreational PA were independently associated with lower risk 338 
with our composite of all-cause mortality plus major CVD, indicating that PA of any type is 339 
beneficial. Of note, high levels of PA was only possible in those individuals participating in non-340 
recreational PA. Indeed, only 2.9% of our study population participated in high level of PA 341 
(≥3000 MET*minutes per week or ≥750 minutes/week of moderate intensity of PA) derived 342 
exclusively from recreational PA compared to 37.9% of participants who attained this level 343 
through non-recreational PA. This reflects the challenges inherent with participating in high 344 
levels of recreational PA in that it is, by definition, conducted during discretionary hours of the 345 
day outside of occupational and domestic duties. In contrast, incorporating PA into one’s daily 346 
lifestyle whether through active transportation, occupation and/or domestic duties has the 347 
potential to achieve higher levels of PA that are associated with even lower risk for mortality and 348 
CVD events. 349 
 350 
To address concerns related to “reverse causality”, we excluded  those with known CVD and 351 
then conducted a sensitivity analysis further excluding those who had events within the first two 352 
years of follow-up. Our results were unchanged for our main study outcomes. In addition, we 353 
also conducted subgroup analyses  stratified by sex, age, body mass index, smoking, presence of 354 
hypertension and presence of diabetes and observed consistent results. We also observed that 355 
increasing  PA  was associated with reduced CVD and non-CVD mortality.  Regular PA has 356 
been reported to be  associated with lower mortality from  certain cancers28,34,36,39 and respiratory 357 
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conditions.40 With continued follow-up, we anticipate accruing enough events to reliably 358 
investigate the effects of PA on specific categories of non-CVD mortality. 359 
 360 
Limitations 361 
While PA determined from the self-reported IPAQ has been found to modestly overestimate PA, 362 
it demonstrates good reliability and moderate validity compared to accelerometers such that 363 
higher IPAQ values correspond to higher levels of PA measured by accelerometers, thus 364 
providing good internal validity.15,41,42 If PA is overestimated by the IPAQ, then the potential 365 
benefits of PA may  be more marked and may occur at lower PA levels than reported here. In 366 
addition, the IPAQ has been tested across a range of countries similar to the PURE study15 and 367 
the use of self-reported measures for assessing PA in large studies is considered acceptable in 368 
low resource settings.43   369 
 370 
While it was not feasible to collect a proportionate sampling of the globe’s population, our 371 
selection of countries and communities ensured that our population was typical of the regions 372 
from which participants were recruited with only modest differences compared to national data ( 373 
Supplementary Appendix for comparative data).44Although we did not recruit a random sample 374 
of individuals, our approach minimized biases in selection of individuals once the communities 375 
were identified. Given the range of countries across five continents at different economic levels  376 
the large number of communities, and the large size of our study, our results are globally 377 
applicable. Given our method of event ascertainment, it is possible that some events may have 378 
been misclassified. However, we believe this to be of very limited numbers as the majority of 379 
events were ascertained using supporting documents, standardized definitions and adjudication 380 
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using standardized definitions providing a high level of confidence in the validity. Lastly, in such 381 
a large study, it is not uncommon to report low p values that may not be clinically relevant, 382 
therefore p values should be interpreted with caution unless they are extreme (p<0.001). Given 383 
the magnitude and consistency of the effects observed across the different analyses, we can be 384 
confident  in our main findings.  385 
 386 
Conclusions 387 
Our findings demonstrate that PA (both recreational and non-recreational) is associated with a 388 
lower risk for mortality and major CVD events., which was  independent of the type of PA, other  389 
risk factors and seen  in all major regions of the world and various country economic levels. In 390 
particular we demonstrate that increasing PA is associated with lower risk in LMIC and LIC for 391 
which limited data existed previously. . Even meeting the minimal PA guidelines such as 392 
walking for as little as 30 minutes on most days of the week had a substantial benefit, while 393 
higher levels of PA (up to and beyond 17 times the recommended PA guidelines) were 394 
associated with  even lower risks.  . As participating in PA (especially in daily life) is 395 
inexpensive, PA is a low cost approach to reducing deaths and CVD that is applicable globally 396 
with potential large impact. The results of our study provide robust evidence to support public 397 
health interventions to increase all forms of PA levels in countries of different socioeconomic 398 
circumstances.45 399 
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Table 1: Participant characteristics stratified by levels of total physical activity (data presented as means ± SD or counts and 
percentage).  
 Overall 
(n = 130 843) 
Low Physical Activity 
(n = 23 631) 
Moderate Physical Activity 
(n = 49 348) 
High Physical Activity 
(n = 57 864) 
Age (years) 50·2 ± 9·7 51·0 ± 10·1 50·5 ± 9·7 49·7 ± 9·5 
Male 54 621 (41·7%) 11 080 (46·9%) 18 224 (36·9%) 25 317 (43·8%) 
Urban resident 69 993 (53·5%) 12 983 (54·9%) 28 525 (57·8%) 28 485 (49·2%) 
Country Income Level     
High 13 546 (10·4%) 1435 (6·1%) 4991 (10·1%) 7120 (12·3%) 
Upper Middle 34 625 (26·5%) 7479 (31·6%) 11 922 (24·2%) 15 224 (26·3%) 
Lower Middle 53 841 (41·1%) 8620 (36·5%) 22 648 (45·9%) 22 573 (39·0%) 
Low 28 831 (22·0%) 6097 (25·8%) 9787 (19·8%) 12 898 (22·4%) 
Education     
None, Primary or 
Unknown 
54 635 (41·9%) 10 642 (45·2%) 19 085 (38·8%) 24 908 (43·1%) 
Secondary 50 500 (38·7%) 9035 (38·3%) 19 746 (40·1%) 21 719 (37·6%) 
Trade, College or 
University 
25 396 (19·5%) 3885 (16·5%) 10 412 (21·1%) 11 099 (19·2%) 
Family History of Heart 
Disease or Stroke 
36 812 (31·3%) 4911 (23·5%) 13 605 (30·5%) 18 296 (35·0%) 
Hypertension 47 752 (39·0%) 9053 (42·6%) 18 364 (39·7%) 20 335 (36·9%) 
Diabetes 12 740 (9·7%) 2898 (12·3%) 5102 (10·3%) 4740 (8·2%) 
Smoker (current and 
former) 
40 955 (31·5%) 7093 (30·3%) 13 695 (28·0%) 20 167 (35·0%) 
Alternate Healthy 
Eating Index score 
35.1 ±8.0 34.9 ±7.6 35.5 ±7.9 34.8 ±8.3 
Body Mass Index 
(kg/m2) 
25·7 ±5·1 25·9 ±5·4 25·9 ±5·0 25·4 ±5·1 
20 
Low physical activity <600 MET*minute/week and <150 minutes/week of moderate intensity physical activity 
Moderate physical activity 600-3000 MET*minute/week and 150-750 minutes/week of moderate intensity physical activity 
High physical activity ≥3000 MET*minute/week and ≥750 minutes/week of moderate intensity physical activity 
Column percentage presented for categorical variables.  
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Table 2: Physical activity by country income level). 
 High Income 
Countries 
(n=13 546) 
Upper Middle 
Income Countries 
(n=34 625) 
Lower Middle 
Income Countries 
(n=53 841) 
Low Income 
Countries 
(n= 28 831) 
P value (for 
heterogeneity) 
P value 
(for trend) 
Total Physical Activity* 
MET*minutes/week 
 
Minutes/week 
 
3227 [1485-6426] 
 
(807 [371-1607]) 
 
2436 [750-5979] 
 
(609 [188-1495]) 
 
2340 [960-5177] 
 
(585 [240-1294]) 
 
2520 [721-6442] 
 
(630 [180-1611]) 
<0·0001 <0·0001 
Recreational Physical 
Activity* 
MET*minutes/week 
 
Minutes/week 
 
 
518 [50-1386] 
 
(130 [12-347]) 
 
 
0 [0-320] 
 
(0 [0-80]) 
 
 
99 [0-693] 
 
(25 [0-173]) 
 
 
0 [0-0] 
 
(0 [0-0]) 
<0·0001 <0·0001 
Non-Recreational 
Physical Activity* 
MET*minutes/week 
 
Minutes/week 
 
 
2115 [806-4980] 
 
(529 [202-1245]) 
 
 
1983 [578-5400] 
 
(496 [144-1350]) 
 
 
1748 [693-4186] 
 
(437 [173-1047]) 
 
 
2297 [594-6222] 
 
(574 [149-1556]) 
<0·0001 0.7762 
Low Physical Activity  1435 (10·6%) 7479 (21·6%) 8620 (16·0%) 6097 (21·1%) <0·0001  
Moderate Physical 
Activity  
4991 (36·8%) 11 922 (34·4%) 22 648 (42·1%) 9787 (33·9%) .  
High Physical Activity  7120 (52·6%) 15 224 (44·0%) 22 573 (41·9%) 12 947 (44·9%) .  
Meeting Physical 
Activity Guidelines † 
12 111 (89·4%) 27 146 (78·4%) 45 221 (84·0%) 22 734 (78·9%) <0·0001 <0·0001 
* presented as median [inter-quartile range (IQR)] in MET*minutes/week and in minutes/week of moderate intensity physical activity  
Low physical activity <600 MET*minute/week and <150 minutes/week of moderate intensity physical activity 
Moderate physical activity 600-3000 MET*minute/week and 150-750 minutes/week of moderate intensity physical activity 
High physical activity ≥3000 MET*minute/week and ≥750 minutes/week of moderate intensity physical activity 
† meeting physical activity guidelines ≥600 MET*minute/week and ≥150 minutes/week of moderate intensity physical activity 
P value for heterogeneity was calculated by Chisq test for categorical variable and Kruskal-Wallis for continuous variable. P value for 
trend was calculated by Cochrane-Armitage test for categorical variable and Jonckheere-Terpstra test for continuous variable.   
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Table 3: Summary of fatal and non-fatal events rates (per 1000 person years) and 95% CI stratified by different levels of physical 
activity, and those meeting, or not meeting, the recommended levels of physical activity. 
 Mortality plus 
Major CVD^ 
Mortality Major CVDˆ CVD Mortality Non-CVD 
Mortality 
Myocardial 
Infarction 
Stroke Heart Failure 
 Events Rate Events Rate Events Rate Events Rate Events Rate Events Rate Events Rate Events Rate 
Low 
physical 
activity (n = 
23 549) 
1941 9·46 
[8·99, 
9·94] 
1396 6·37 
[5·99, 
6·76] 
1000 5·13 
[4·78, 
5·48] 
377 1·75 
[1·55, 
1·94] 
1019 4·63 
[4·30, 
4·96] 
496 2·64 
[2·39, 
2·89] 
427 2·09 
[1·87, 
2·31] 
84 0·42 
[0·32, 
0·52] 
Moderate 
physical 
activity (n = 
49 245) 
3002 7·14 
[6·86, 
7·43] 
1881 4·25 
[4·04, 
4·47] 
1682 4·13 
[3·91, 
4·34] 
480 1·12 
[1·01, 
1·23] 
1401 3·13 
[2·95, 
3·32] 
730 1·86 
[1·71, 
2·00] 
820 1·93 
[1·79, 
2·08] 
144 0·34 
[0·27, 
0·40] 
High 
physical 
activity (n = 
57 725) 
3233 6·60 
[6·36, 
6·84] 
2057 4·11 
[3·92, 
4·30] 
1718 3·53 
[3·35, 
3·70] 
437 0·87 
[0·78, 
0·96] 
1620 3·24 
[3·07, 
3·40] 
761 1·58 
[1·47, 
1·70] 
839 1·68 
[1·56, 
1·80] 
158 0·30 
[0·25, 
0·36] 
P value for 
trend 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p=0·00
10 
 p=0·09
97 
Not meeting 
guidelines 
(n=23 549) 
1941 9·46 
[8·99, 
9·94] 
1396 6·37 
[5·99, 
6·76] 
1000 5·13 
[4·78, 
5·48] 
377 1·75 
[1·55, 
1·94] 
1019 4·63 
[4·30, 
4·96] 
496 2·64 
[2·39, 
2·89] 
427 2·09 
[1·87, 
2·31] 
84 0·42 
[0·32, 
0·52] 
Meeting 
guidelines 
(n=106 970) 
6235 6·86 
[6·68, 
7·05] 
3938 4·19 
[4·05, 
4·33] 
3400 3·80 
[3·66, 
3·94] 
917 0·98 
[0·92, 
1·05] 
3021 3·21 
[3·08, 
3·33] 
1491 1·71 
[1·62, 
1·81] 
1659 1·79 
[1·70, 
1·88] 
302 0·32 
[0·28, 
0·35] 
P value for 
trend 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p<0·00
01 
 p=0·00
88 
 p=0·03
76 
Event rates are standardized for age and sex. 
Low physical activity <600 MET*minutes/week; moderate physical activity 600-3000 MET*minutes/week; high physical activity 
≥3000 MET*minutes/week 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident myocardial infarction, stroke, and heart failure 
A maximum of one event per participant is tabulated for each outcome. 
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Figure 1: Hazard ratios and 95% CI for the pairwise comparison between levels of total physical activity, adjusted for age, sex, 
education, country income level, urban/rural residency, family history of CVD and smoking status taking into account household, 
community and country clustering. There were 3155, 2041 and 1723 events for all-cause mortality and major CVD, all-cause 
mortality, and major CVD, respectively. 
Low physical activity level <600 MET*minute/week; moderate physical activity 600-3000 MET*minute/week; high physical activity 
≥3000 MET*minute/week  
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure. The p values of the first column show the significance of 
each comparison. P-values of the second column show the significance of the overall effect of PA level.
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Figure 2: Hazard ratios and 95% CI of level of total physical activity for mortality (adjusted for 
age, sex, education, country income level, urban/rural residency, family history of cardiovascular 
disease and smoking status taking into account household, community and country clustering). 
Based on data for 115 436 participants with complete data. 
Note: Low physical activity level (<600 MET*minute/week) is the reference group. 
Moderate physical activity 600-3000 MET*minute/week; high physical activity ≥3000 
MET*minute/week 
BMI = body mass index; WHR = waist to hip ratio (high WHR was defined as above 0.85 for 
female and above 0.9 for male) 
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Relationship between PA Type with Mortality and Major CVD expressed MET*min/week 
 
 
Relationship between PA Type with Mortality and Major CVD expressed min/week of Moderate Intensity PA 
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Figure 3: Relationship between increasing total physical activity (PA; left panels), recreational PA (middle panels) and non-
recreational PA (occupational, transportation and housework PA; right panels) with mortality and major cardiovascular disease (CVD) 
presented in MET*minutes/week (top panels) and minutes/week of moderate intensity PA (bottom panels). Models were adjusted for 
age, sex, education, country income level, urban/rural residency, family history of CVD and smoking status, taking into account 
household, community and country clustering. Recreational PA was truncated at 3000 MET*minutes/week and 750 minutes/week of 
moderate intensity PA due to sparse observation above that level. 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure 
HR = hazard ratio 
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Table 4. Summary of risk (hazards ratio) of mortality and major CVD events stratified by 
country income level and physical activity levels.  
  Mortality plus 
Major CVD^ 
Mortality Major CVDˆ 
High Income 
Countries 
Events 548 259 335 
Moderate PA 0·70 [0·54, 0.91] 0·69 [0·48, 1·00] 0·62 [0·44, 0·86] 
High PA 0·58 [0·45, 0·76] 0·54 [0·38, 0·78] 0·53 [0·38, 0·72] 
P value 0.0550 0.0818 0.1891 
Upper Middle 
Income Countries 
Events 1665 1150 836 
Moderate PA 0·82 [0·72, 0·93] 0·77 [0·66, 0·89] 0·86 [0·72, 1·03] 
High PA 0·65 [0·57, 0·74] 0·63 [0·54, 0·73] 0·64 [0·54, 0·77] 
P value <0·0001 0.0056 0.0004 
Lower Middle 
Income Countries 
Events 2811 1343 1852 
Moderate PA 0·99 [0·89, 1.10] 0·94 [0·81, 1·08] 0·94 [0·82, 1.07] 
High PA 0·92 [0·82, 1.02] 0·79 [0·68, 0·92] 0·94 [0·83, 1.08] 
P value 0.0741 0.0043 0.8913 
Low Income 
Countries 
Events 1579 1203 804 
Moderate PA 0·76 [0·67, 0·87] 0·73 [0·63, 0·85] 0·83 [0·69, 1.00] 
High PA 0·61 [0·53, 0·69] 0·58 [0·50, 0·66] 0·63 [0·53, 0·75] 
P value 0.0002 0.0010 0.0013 
Hazard ratios (and 95% CI) were adjusted for age, sex, education, country income level, 
urban/rural residency, family history of CVD and smoking status taking into account household, 
community and country clustering. 
Note: Low physical activity level (<600 MET*minute/week) is the reference group. 
Moderate physical activity 600-3000 MET*minute/week; high physical activity ≥3000 
MET*minute/week 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure 
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Figure 4: Relationship between increasing levels of total physical activity (PA; left panel), recreational PA (middle panel) and non-
recreational PA (occupational, transportation and housework PA; right panel) with mortality and major cardiovascular disease (CVD) 
stratified by country income level. Models were adjusted for age, sex, education, country income level, urban/rural residency, family 
history of CVD and smoking status, taking into account household, community and country clustering. 
HIC+UMIC = high income countries plus upper middle income countries 
LMIC+LIC = lower middle income countries plus low income countries 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure 
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Supplemental Table 1: Summary of fatal and non-fatal events rates (per 1000 person years) and 95% CI stratified by country income 
level. 
 Mortality plus 
Major CVD^ 
Mortality Major CVDˆ CVD Mortality Non-CVD 
Mortality 
Myocardial 
Infarction 
Stroke Heart Failure 
 Events Rate Events Rate Events Rate Events Rate Events Rate Events Rate Events Rate Events Rate 
High 
Income 
Countries 
548 4·06 
[3·67, 
4·45] 
259 1·79 
[1·53, 
2·04] 
335 2·57 
[2·25, 
2·88] 
30 0·22 
[0·13, 
0·32] 
229 1·56 
[1·33, 
1·80] 
155 1·24 
[1·02, 
1·46] 
142 1·03 
[0·84, 
1·23] 
50 0·34 
[0·22, 
0·45] 
Upper 
Middle 
Income 
Countries 
1690 7·08 
[6·71, 
7·44] 
1171 4·65 
[4·36, 
4·94] 
843 3·66 
[3·40, 
3·92] 
270 1·07 
[0·94, 
1·21] 
901 3·57 
[3·32, 
3·83] 
407 1·79 
[1·61, 
1·98] 
311 1·33 
[1·17, 
1·48] 
139 0·57 
[0·47, 
0·68] 
Lower 
Middle 
Income 
Countries 
2863 6·23 
[5·98, 
6·48] 
1371 2·92 
[2·75, 
3·09] 
1884 4·11 
[3·91, 
4·31] 
293 0·64 
[0·56, 
0·72] 
1078 2·28 
[2·13, 
2·43] 
583 1·31 
[1·19, 
1·42] 
1206 2·59 
[2·43, 
2·74] 
127 0·27 
[0·21, 
0·32] 
Low Income 
Countries 
3075 10·75 
[10·34, 
11·16] 
2533 8·49 
[8·13, 
8·86] 
1338 4·87 
[4·59, 
5·15] 
701 2·37 
[2·18, 
2·57] 
1832 6·12 
[5·81, 
6·43] 
842 3·12 
[2·89, 
3·34] 
427 1·48 
[1·33, 
1·63] 
70 0·24 
[0·18, 
0·30] 
Total 8176 7·32 
[7·15, 
7·49] 
5334 4·57 
[4·44, 
4·71] 
4400 4·03 
[3·90, 
4·16] 
1294 1·12 
[1·05, 
1·19] 
4040 3·46 
[3·34, 
3·57] 
1987 1·87 
[1·79, 
1·96] 
2086 1·84 
[1·76, 
1·93] 
386 0·33 
[0·30, 
0·37] 
Event rates are standardized for age and sex. 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident myocardial infarction, stroke, and heart failure 
A maximum of one event per participant is tabulated for each outcome. 
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Supplemental Table 2: Summary of risk (hazard ratios) for mortality and major CVD events compared by physical activity (PA) levels 
(adjusted for wealth index in place of education). 
 Mortality plus Major CVD^ Mortality Major CVDˆ 
 HR P value HR P value HR P value 
Moderate PA vs. 
Low PA 
0.85 [0.80,0.91] <0·0001 0.80 [0.74,0.87] <0·0001 0.86 [0.79,0.94] 0·0008 
High PA vs. Low 
PA 
0.73 [0.68,0.78] <0·0001 0.66 [0.60,0.71] <0·0001 0.76 [0.69,0.83] <0·0001 
High PA vs. 
Moderate PA 
0.85 [0.81,0.90] <0·0001 0.82 [0.76,0.88] <0·0001 0.88 [0.82,0.95] 0·0007 
Hazard ratios (and 95% CI) were adjusted for age, sex, wealth index, country income level, urban/rural residency, family history of 
CVD and smoking status taking into account household, community and country clustering. 
Low PA level <600 MET*minute/week; Moderate PA 600-3000 MET*minute/week; High physical activity ≥3000 
MET*minute/week 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure 
 
Supplemental Table 3: Summary of risk (hazard ratios) for mortality and major CVD events compared by physical activity (PA) levels 
(adjusted for household income in place of education). 
 Mortality plus Major CVD^ Mortality Major CVDˆ 
 HR P value HR P value HR P value 
Moderate PA vs. 
Low PA 
0.85 [0.80,0.91] <0·0001 0.80 [0.74,0.88] <0·0001 0.87 [0.79,0.95] 0·002 
High PA vs. Low 
PA 
0.72 [0.68,0.78] <0·0001 0.64 [0.59,0.70] <0·0001 0.77 [0.70,0.84] <0·0001 
High PA vs. 
Moderate PA 
0.85 [0.80,0.90] <0·0001 0.80 [0.74,0.87] <0·0001 0.88 [0.82,0.95] 0·0013 
Hazard ratios (and 95% CI) were adjusted for age, sex, household income, country income level, urban/rural residency, family history 
of CVD and smoking status taking into account household, community and country clustering. 
Low PA level <600 MET*minute/week; Moderate PA 600-3000 MET*minute/week; High physical activity ≥3000 
MET*minute/week 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure  
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Supplemental Table 4: Summary of risk (hazard ratios) for mortality and major CVD events compared by physical activity (PA) 
levels. 
 Mortality plus Major CVD^ Mortality Major CVDˆ 
 HR P value HR P value HR P value 
Moderate PA vs. 
Low PA 
0·85 [0·80, 0·91] <0·0001 0·80 [0·74 ,0·87] <0·0001 0·86 [0·79, 0·93] 0·0004 
Lower high PA 
vs. Moderate PA 
0·88 [0·82 ,0·94] 0·0002 0·83 [0·76 ,0·91] <0·0001 0·92 [0·84, 1·00] 0·0528 
Upper high PA 
vs. Lower high 
PA 
0·93 [0·86, 1·01] 0·0807 0·95 [0·85, 1·05] 0·2896 0·91 [0·82, 1·01] 0·0817 
Hazard ratios (and 95% CI) were adjusted for age, sex, education, country income level, urban/rural residency, family history of CVD 
and smoking status taking into account household, community and country clustering. 
Low PA level <600 MET*minute/week; Moderate PA 600-3000 MET*minute/week; Lower high PA 3000-6453 MET*minute/week; 
Higher high PA ≥6453 MET*minute/week 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure 
  
32 
Supplemental Table 5: Summary of risk (hazard ratios) for major CVD events stratified by physical activity (PA) level.  
 CVD Mortality Non-CVD Mortality Myocardial Infarction Stroke Heart Failure 
Moderate PA 0·75 [0·64, 0·88] 0·83 [0·75, 0·91] 0·78 [0·68, 0·89] 0·93 [0·82, 1·06] 0·83 [0·63, 1·11] 
High PA 0·58 [0·49, 0·68] 0·68 [0·62, 0·75] 0·67 [0·59, 0·76] 0·85 [0·75, 0·96] 0·76 [0·58, 1·01] 
P value for 
trend 
p=0·0010 p<·0001 p=0·0100 p=0·0716 p=0·4794 
Hazard ratios (and 95% CI) were adjusted for age, sex, education, country income level, urban/rural residency, family history of CVD 
and smoking status taking into account household, community and country clustering. 
Note: Low physical activity level (<600 MET*minute/week) is the reference group. 
Moderate physical activity 600-3000 MET*minute/week; high physical activity ≥3000 MET*minute/week CVD = cardiovascular 
disease 
 
 
 
Supplemental Table 6: Summary of risk (hazard ratios) for mortality and major CVD events stratified by physical activity (PA) level 
with the additional adjustment for body mass index. 
 Mortality plus 
Major CVD^ 
Mortality Major CVD ˆ CVD 
Mortality 
Non-CVD 
Mortality 
Myocardial 
Infarction 
Stroke Heart Failure 
Moderate 
PA 
0·88 [0·82, 
0·94] 
0·84 [0·77, 
0·92] 
0·88 [0·80, 
0·96] 
0·80 [0·67, 
0·96] 
0·85 [0·77, 
0·94] 
0·81 [0·71, 
0·93] 
0·96 [0·84, 
1·09] 
0·83 [0·62, 
1·12] 
High PA 0·76 [0·71, 
0·81] 
0·69 [0·63, 
0·75] 
0·79 [0·72, 
0·86] 
0·64 [0·54, 
0·76] 
0·71 [0·64, 
0·78] 
0·71 [0·62, 
0·82] 
0·87 [0·77, 
0·99] 
0·81 [0·61, 
1·08] 
P value 
for trend 
p<0·0001 p<0·0001 p=0·0056 p=0·0059 p<0·0001 p=0·0358 p=0·0926 p=0·8712 
Hazard ratios (and 95% CI) were adjusted for age, sex, education, country income level, urban/rural residency, family history of CVD, 
body mass index and smoking status taking into account household, community and country clustering. 
Note: Low physical activity level (<600 MET*minute/week) is the reference group. 
Moderate physical activity 600-3000 MET*minute/week; high physical activity ≥3000 MET*minute/week 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure 
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Supplemental Table 7: Summary of risk (hazard ratios) for mortality and major CVD events stratified by physical activity (PA) level 
(excluding participants with CVD events in first two years of follow-up). 
 Mortality plus 
Major CVD^ 
Mortality Major CVD ˆ CVD 
Mortality 
Non-CVD 
Mortality 
Myocardial 
Infarction 
Stroke Heart Failure 
Moderate 
PA 
0·89 [0·83, 
0·96] 
0·85 [0·78, 
0·93] 
0·87 [0·79, 
0·96] 
0·76 [0·63, 
0·93] 
0·88 [0·79, 
0·98] 
0·80 [0·69, 
0·93] 
0·95 [0·83, 
1·09] 
0·77 [0·56, 
1·06] 
High PA 0·77 [0·71, 
0·83] 
0·69 [0·63, 
0·76] 
0·80 [0·73, 
0·89] 
0·64 [0·53, 
0·77] 
0·71 [0·64, 
0·79] 
0·75 [0·65, 
0·87] 
0·88 [0·77, 
1·02] 
0·78 [0·57, 
1·06] 
P value 
for trend 
p<0·0001 p<0·0001 p=0·0492 p=0·0533 p<0·0001 p=0·3588 p=0·1996 p=0·9531 
Hazard ratios (and 95% CI) were adjusted for age, sex, education, country income level, urban/rural residency, family history of CVD 
and smoking status taking into account household, community and country clustering. 
Note: Low physical activity level (<600 MET*minute/week) is the reference group. 
Moderate physical activity 600-3000 MET*minute/week; high physical activity ≥3000 MET*minute/week CVD = cardiovascular 
disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure 
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Supplemental Figure 1: Adjusted survival curves for mortality and major cardiovascular disease (CVD) (left panel), mortality (middle 
panel) and major CVD (CVD mortality plus incident MI, stroke, and heart failure; right panel) stratified by level of physical activity 
(PA). All models adjusted for age, sex, education, country income level, urban/rural residency, family history of CVD and smoking 
status, taking into account household, community and country clustering. 
Low physical activity <600 MET*minute/week; moderate physical activity 600-3000 MET*minute/week; high physical activity 
≥3000 MET*minute/week 
P values corresponding to testing heterogeneity of the three curves in each panel  
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Supplemental Figure 2. Adjusted 5-year population attributable fraction and 95% CI of not meeting physical activity (PA) guideline 
(gray bars) and of not participating high PA (black bars). Meaning a proportion reduction in the outcomes by 5 years if the entire 
population met PA guidelines (gray bars) and if entire population achieved high physical activity (≥3000 MET*minute/week; black 
bars). (Adjusted for age, sex, education, country income level, urban/rural residency, family history of CVD and smoking status, 
taking into account household, community and country clustering). 
CVD = cardiovascular disease 
ˆMajor CVD = CVD mortality plus incident MI, stroke, and heart failure
36 
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